Literature DB >> 16700077

Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002.

Julien Mancini1, Xavier Thirion, Alain Masut, Carine Saillard, Vincent Pradel, Fanny Romain, Marie-Joseph Jean Pastor, Christine Coudert, Joëlle Micallef.   

Abstract

PURPOSE: This study proposes to complete declarative studies by describing the prescriptions of anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002.
METHODS: This cross-sectional study analyzes all the hypnotic, anxiolytic, and antidepressant prescriptions (ATC codes beginning with N05B, N05C, and N06A, respectively) sent by adolescents (aged 13-17 years) to the French Health Insurance system of the study region for reimbursement during one year (2002). It was performed in a southern France area with 120,908 adolescents covered by this insurance scheme. Adverse drug reactions (ADRs) recorded in the Pharmacovigilance database were also studied.
RESULTS: Three thousand two hundred and eighty-six adolescents (2.7% of adolescent population) had at least one prescription of the studied drugs. This prevalence increased with age and female sex, leading to a maximum of 6.3% for the 17-year-old girls. Two thousand four hundred and thirty-one of adolescents were dispensed anxiolytics, 935 antidepressants, and 548 hypnotics. The most dispensed drugs were zolpidem, zopiclone, and niaprazine for hypnotics; hydroxyzine, etifoxine, and bromazepam for anxiolytics; and paroxetine, sertraline, and fluoxetine for antidepressants. Zolpidem, hydroxyzine, and paroxetine accounted, respectively, for 82.9%, 57.1%, and 59.8% of the prescriptions. 75.5% of hypnotics users had only one prescription, 77.4% for anxiolytics, and 57.4% for antidepressants. Three ADRs were reported.
CONCLUSIONS: This study confirms the large use of psychotropics in French adolescents and the influence of age and sex. Also, the results underline treatment for most adolescents is short, which may be beneficial for hypnotics and anxiolytics but not for antidepressants. Copyright (c) 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16700077     DOI: 10.1002/pds.1258

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  6 in total

Review 1.  Recent international trends in psychotropic medication prescriptions for children and adolescents.

Authors:  Hans-Christoph Steinhausen
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-11-08       Impact factor: 4.785

2.  Study of Natural products Adverse Reactions (SONAR) in children seen in mental health clinics: a cross-sectional study.

Authors:  Emma Sparks; Liliane Zorzela; Candace Necyk; Baljit Khamba; Liana Urichuk; Joanne Barnes; Sunita Vohra
Journal:  BMJ Paediatr Open       Date:  2020-09-28

Review 3.  Pharmacovigilance in children: detecting adverse drug reactions in routine electronic healthcare records. A systematic review.

Authors:  Corri Black; Nara Tagiyeva-Milne; Peter Helms; Dorothy Moir
Journal:  Br J Clin Pharmacol       Date:  2015-05-28       Impact factor: 4.335

4.  Psychotropic medication in the French child and adolescent population: prevalence estimation from health insurance data and national self-report survey data.

Authors:  Eric Acquaviva; Stéphane Legleye; Guy R Auleley; Jean Deligne; Didier Carel; Bruno Falissard B
Journal:  BMC Psychiatry       Date:  2009-11-17       Impact factor: 3.630

Review 5.  Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases: Illustration From the Experience of the French Addictovigilance Network.

Authors:  Thomas Soeiro; Clémence Lacroix; Vincent Pradel; Maryse Lapeyre-Mestre; Joëlle Micallef
Journal:  Front Psychiatry       Date:  2021-05-17       Impact factor: 4.157

6.  A three-country comparison of psychotropic medication prevalence in youth.

Authors:  Julie M Zito; Daniel J Safer; Lolkje T W de Jong-van den Berg; Katrin Janhsen; Joerg M Fegert; James F Gardner; Gerd Glaeske; Satish C Valluri
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2008-09-25       Impact factor: 3.033

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.